These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
410 related articles for article (PubMed ID: 33014289)
1. Advances in epidermal growth factor receptor specific immunotherapy: lessons to be learned from armed antibodies. Biteghe FAN; Mungra N; Chalomie NET; Ndong JC; Engohang-Ndong J; Vignaux G; Padayachee E; Naran K; Barth S Oncotarget; 2020 Sep; 11(38):3531-3557. PubMed ID: 33014289 [TBL] [Abstract][Full Text] [Related]
2. EGFR targeting for cancer therapy: Pharmacology and immunoconjugates with drugs and nanoparticles. Santos EDS; Nogueira KAB; Fernandes LCC; Martins JRP; Reis AVF; Neto JBV; Júnior IJDS; Pessoa C; Petrilli R; Eloy JO Int J Pharm; 2021 Jan; 592():120082. PubMed ID: 33188892 [TBL] [Abstract][Full Text] [Related]
3. Targeted human cytolytic fusion proteins at the cutting edge: harnessing the apoptosis-inducing properties of human enzymes for the selective elimination of tumor cells. Mungra N; Jordaan S; Hlongwane P; Naran K; Chetty S; Barth S Oncotarget; 2019 Jan; 10(8):897-915. PubMed ID: 30783518 [TBL] [Abstract][Full Text] [Related]
4. Targeting epidermal growth factor receptor in solid tumors: critical evaluation of the biological importance of therapeutic monoclonal antibodies. Gialeli Ch; Kletsas D; Mavroudis D; Kalofonos HP; Tzanakakis GN; Karamanos NK Curr Med Chem; 2009; 16(29):3797-804. PubMed ID: 19747140 [TBL] [Abstract][Full Text] [Related]
5. Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entities. Niesen J; Stein C; Brehm H; Hehmann-Titt G; Fendel R; Melmer G; Fischer R; Barth S J Cancer Res Clin Oncol; 2015 Dec; 141(12):2079-95. PubMed ID: 25899161 [TBL] [Abstract][Full Text] [Related]
6. The efficient elimination of solid tumor cells by EGFR-specific and HER2-specific scFv-SNAP fusion proteins conjugated to benzylguanine-modified auristatin F. Woitok M; Klose D; Niesen J; Richter W; Abbas M; Stein C; Fendel R; Bialon M; Püttmann C; Fischer R; Barth S; Kolberg K Cancer Lett; 2016 Oct; 381(2):323-30. PubMed ID: 27502168 [TBL] [Abstract][Full Text] [Related]
7. Induction of anti-EGFR immune response with mimotopes identified from a phage display peptide library by panitumumab. Wang A; Cui M; Qu H; Di J; Wang Z; Xing J; Wu F; Wu W; Wang X; Shen L; Jiang B; Su X Oncotarget; 2016 Nov; 7(46):75293-75306. PubMed ID: 27659529 [TBL] [Abstract][Full Text] [Related]
8. Improving the efficacy of Photoimmunotherapy (PIT) using a cocktail of antibody conjugates in a multiple antigen tumor model. Nakajima T; Sano K; Choyke PL; Kobayashi H Theranostics; 2013; 3(6):357-65. PubMed ID: 23781283 [TBL] [Abstract][Full Text] [Related]
12. Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model. Reusch U; Sundaram M; Davol PA; Olson SD; Davis JB; Demel K; Nissim J; Rathore R; Liu PY; Lum LG Clin Cancer Res; 2006 Jan; 12(1):183-90. PubMed ID: 16397041 [TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor (EGFR) involvement in epithelial-derived cancers and its current antibody-based immunotherapies. London M; Gallo E Cell Biol Int; 2020 Jun; 44(6):1267-1282. PubMed ID: 32162758 [TBL] [Abstract][Full Text] [Related]
14. Targeted therapy of solid tumors by monoclonal antibody specific to epidermal growth factor receptor. Baradaran B; Majidi J; Farajnia S; Barar J; Omidi Y Hum Antibodies; 2014; 23(1-2):13-20. PubMed ID: 25812698 [TBL] [Abstract][Full Text] [Related]
15. KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis. Medical Advisory Secretariat Ont Health Technol Assess Ser; 2010; 10(25):1-49. PubMed ID: 23074403 [TBL] [Abstract][Full Text] [Related]
16. Genetically engineered monoclonal antibodies for direct anti-neoplastic treatment and cancer cell specific delivery of chemotherapeutic agents. Bodey B; Bodey B; Siegel SE; Kaiser HE Curr Pharm Des; 2000 Feb; 6(3):261-76. PubMed ID: 10637379 [TBL] [Abstract][Full Text] [Related]
17. Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies. Riemer AB; Kurz H; Klinger M; Scheiner O; Zielinski CC; Jensen-Jarolim E J Natl Cancer Inst; 2005 Nov; 97(22):1663-70. PubMed ID: 16288119 [TBL] [Abstract][Full Text] [Related]
18. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies. Bodey B; Siegel SE; Kaiser HE Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112 [TBL] [Abstract][Full Text] [Related]
19. Enhancement of tumor uptake and therapeutic efficacy of EGFR-targeted antibody cetuximab and antibody-drug conjugates by cholesterol sequestration. Chen Y; Liu G; Guo L; Wang H; Fu Y; Luo Y Int J Cancer; 2015 Jan; 136(1):182-94. PubMed ID: 24798787 [TBL] [Abstract][Full Text] [Related]
20. 177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model. Liu Z; Ma T; Liu H; Jin Z; Sun X; Zhao H; Shi J; Jia B; Li F; Wang F Mol Pharm; 2014 Mar; 11(3):800-7. PubMed ID: 24472064 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]